EHA 2015 | Considerations for drug development in hematological oncology

Name: Considerations for drug development in hematological oncology
Uploaded: 2015-06-12T00:00:00.000Z
Duration: 5 min 6 s
Description: At the 20th Congress of the European Hematology Association (EHA), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, highlights the progress of novel therapeutic agents and approaches in the field of hematological oncology and the need to find a balance between health care affordability and profits that will allow this continued innovation.

Matti Aapro • 12 Jun 2015

EHA 2015

General

At the 20th Congress of the European Hematology Association (EHA), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, highlights the progress of novel therapeutic agents and approaches in the field of hematological oncology and the need to find a balance between health care affordability and profits that will allow this continued innovation.